MX2022007905A - Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. - Google Patents
Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos.Info
- Publication number
- MX2022007905A MX2022007905A MX2022007905A MX2022007905A MX2022007905A MX 2022007905 A MX2022007905 A MX 2022007905A MX 2022007905 A MX2022007905 A MX 2022007905A MX 2022007905 A MX2022007905 A MX 2022007905A MX 2022007905 A MX2022007905 A MX 2022007905A
- Authority
- MX
- Mexico
- Prior art keywords
- temperature
- cells
- subject
- sensitive
- methods
- Prior art date
Links
- 108091005461 Nucleic proteins Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 230000001052 transient effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 7
- 230000000694 effects Effects 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000036757 core body temperature Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/128—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes processing or releasing ribozyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18641—Use of virus, viral particle or viral elements as a vector
- C12N2760/18643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18822—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955801P | 2019-12-31 | 2019-12-31 | |
| US202062992700P | 2020-03-20 | 2020-03-20 | |
| PCT/US2020/067506 WO2021138447A1 (en) | 2019-12-31 | 2020-12-30 | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007905A true MX2022007905A (es) | 2022-08-25 |
Family
ID=76687429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007905A MX2022007905A (es) | 2019-12-31 | 2020-12-30 | Administracion transitoria basada en temperatura de acidos nucleicos y proteinas a celulas y tejidos. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11421248B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4085130A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7787075B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102764120B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116134131A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020417800A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3162690A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL294290A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007905A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021138447A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| KR102764120B1 (ko) | 2019-12-31 | 2025-02-06 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Vlp醫療股份有限公司 | 冠狀病毒疫苗 |
| CN118490818A (zh) | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| MX2023014564A (es) * | 2021-06-17 | 2024-03-05 | Elixirgen Therapeutics Inc | Vacunas de arn autorreplicante, controlables por temperatura, para enfermedades virales. |
| JP2024533123A (ja) * | 2021-09-02 | 2024-09-12 | エリクサージェン セラピューティクス,インコーポレイティド | がんのための温度制御可能なrna免疫療法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| EP4473544A1 (en) * | 2022-02-04 | 2024-12-11 | Elixirgen Therapeutics, Inc. | Cell therapy protocol systems and methods |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024112821A1 (en) | 2022-11-22 | 2024-05-30 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| EP0819250B1 (en) | 1995-04-06 | 2006-09-20 | Miltenyi Biotec Inc. | Multiparameter cell separation using releasable colloidal magnetic particles |
| US6458560B1 (en) | 1996-04-05 | 2002-10-01 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| AU757549B2 (en) | 1998-03-27 | 2003-02-27 | Cytos Biotechnology Ag | Inducible alphaviral gene expression system |
| AU4932199A (en) | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| CA2373300C (en) | 1999-04-14 | 2012-02-21 | Chiron Corporation | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| WO2000070070A1 (en) | 1999-05-18 | 2000-11-23 | Dnavec Research Inc. | Paramyxoviridae virus vector defective in envelope gene |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| BR0313113A (pt) | 2002-08-13 | 2005-06-28 | Akzo Nobel Nv | Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina |
| US7820181B2 (en) * | 2002-09-18 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens |
| WO2004055161A2 (en) | 2002-12-12 | 2004-07-01 | The Board Of Regents Of The University Of Texas System | Large scale production of packaged alphavirus replicons |
| AU2003297041B2 (en) | 2002-12-13 | 2009-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
| EP1608762B1 (en) | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
| US20050282279A1 (en) * | 2003-05-29 | 2005-12-22 | Hwu Paul L | Expression vector encoding coronavirus-like particle |
| WO2004108937A1 (en) * | 2003-06-04 | 2004-12-16 | Bioleaders Corporation | Cell surface expression vector of sars virus antigen and microorganisms transformed thereby |
| US7541038B2 (en) | 2003-06-05 | 2009-06-02 | Wyeth Holdings Corporation | Fusogenic, self-propagating blebs as immunogenic compositions |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| US7998733B2 (en) | 2004-10-05 | 2011-08-16 | Merial Limited | Chimeric vectors |
| JP4478788B2 (ja) | 2005-05-27 | 2010-06-09 | 独立行政法人産業技術総合研究所 | センダイウイルス温度感受性株由来のウイルスベクター |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| WO2007098267A2 (en) | 2006-02-27 | 2007-08-30 | The Board Of Regents Of The University Of Texas System | Pseudoinfectious flavivirus and uses thereof |
| US20090047255A1 (en) | 2006-11-03 | 2009-02-19 | Alphavax, Inc. | Alphavirus and Alphavirus Replicon Particle Formulations and Methods |
| MX352947B (es) | 2007-02-27 | 2017-12-14 | Int Inst Cancer Immunology Inc | Metodo para activacion de celula t auxiliar y composicion para usarse en el metodo. |
| US8748591B2 (en) | 2007-04-17 | 2014-06-10 | The Board Of Regents Of The University Of Texas System | Chimeric sindbis-western equine encephalitis virus and uses thereof |
| EP2143794A1 (en) * | 2007-04-27 | 2010-01-13 | Kyushu University, National University Corporation | Viral vector for gene therapy |
| WO2009079185A2 (en) * | 2007-11-26 | 2009-06-25 | Novartis Vaccines And Diagnostics, Inc. | Methods of generating alphavirus particles |
| WO2009072610A1 (ja) | 2007-12-05 | 2009-06-11 | International Institute Of Cancer Immunology, Inc. | 癌ワクチン組成物 |
| JP5758632B2 (ja) | 2008-01-24 | 2015-08-05 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System | 蚊において複製不可能な弱毒化組み換えアルファウイルス属及びそれらの使用 |
| EP2130912A1 (en) | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
| WO2010008054A1 (ja) | 2008-07-16 | 2010-01-21 | ディナベック株式会社 | 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法 |
| EP2451475A2 (en) | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| KR102266691B1 (ko) | 2010-10-11 | 2021-06-23 | 노파르티스 아게 | 항원 전달 플랫폼 |
| US9402890B2 (en) | 2011-02-01 | 2016-08-02 | Uab Research Foundation | Methods and compositions for pseudoinfectious alphaviruses |
| US9636410B2 (en) * | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| EP3520810A3 (en) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Immunogenic wt1 peptides and use thereof |
| AU2013266496B2 (en) | 2012-05-21 | 2018-08-09 | The Regents Of The University Of California | Generation of human iPS cells by a synthetic self- replicative RNA |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| WO2014089513A1 (en) | 2012-12-06 | 2014-06-12 | Synthetic Genomics, Inc. | Autonomous replication sequences and episomal dna molecules |
| LT2945647T (lt) | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| WO2014134539A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
| EP2968392B1 (en) | 2013-03-15 | 2020-08-05 | Elixirgen Therapeutics, Inc. | Methods of using zscan4 for rejuvenating human cells |
| US12374421B2 (en) | 2013-06-10 | 2025-07-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2015046229A1 (ja) | 2013-09-24 | 2015-04-02 | ディナベック株式会社 | 多能性幹細胞の誘導効率を改善する方法 |
| AU2014369774B2 (en) * | 2013-12-20 | 2020-11-26 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus variant, European PRRS virus cDNA clone, and uses thereof |
| US10174317B2 (en) | 2014-02-13 | 2019-01-08 | Synthetic Genomics, Inc. | Recombinant RNA particles and methods of use |
| US10266834B2 (en) | 2014-02-13 | 2019-04-23 | Synthetic Genomics, Inc. | Recombinant RNA particles and methods of producing proteins |
| JP6769880B2 (ja) | 2015-02-02 | 2020-10-14 | 株式会社Idファーマ | 改良されたマイナス鎖rnaウイルスベクター |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| JP6913032B2 (ja) * | 2015-05-20 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | 共通ネオ抗原 |
| US10695385B2 (en) | 2015-06-25 | 2020-06-30 | National University Corporation Kobe University | Oral cancer vaccine |
| WO2017015457A1 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Ebola vaccine |
| WO2017026776A1 (en) | 2015-08-10 | 2017-02-16 | Cellivery Therapeutics, Inc. | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof |
| US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| DK3375874T3 (da) | 2015-11-13 | 2022-05-09 | Id Pharma Co Ltd | Forbedret paramyxovirus-vektor |
| SG11201804197RA (en) | 2015-11-18 | 2018-06-28 | Orbis Health Solutions Llc | T7 alpha viral vector system |
| HUE059694T2 (hu) | 2015-11-20 | 2022-12-28 | Memorial Sloan Kettering Cancer Center | Készítmény rák kezelésére |
| GB201603374D0 (en) | 2016-02-26 | 2016-04-13 | Ucl Business Plc | Packaging cell |
| WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
| WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| WO2017208191A1 (en) | 2016-06-02 | 2017-12-07 | Glaxosmithkline Biologicals Sa | Zika viral antigen constructs |
| US20190216956A1 (en) * | 2016-07-27 | 2019-07-18 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| ES2993107T3 (en) | 2016-10-17 | 2024-12-23 | Janssen Pharmaceuticals Inc | Recombinant virus replicon systems and uses thereof |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| WO2018081318A1 (en) * | 2016-10-25 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| WO2018161092A1 (en) | 2017-03-03 | 2018-09-07 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| WO2018170347A1 (en) * | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| US11015204B2 (en) | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| KR102823029B1 (ko) | 2017-12-20 | 2025-06-20 | 브이엘피 테라퓨틱스 인코포레이티드 | 알파바이러스 레플리콘 입자 |
| KR20200111729A (ko) | 2018-01-19 | 2020-09-29 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 |
| CN118436618A (zh) | 2018-05-30 | 2024-08-06 | 川斯勒佰尔公司 | 信使rna疫苗及其用途 |
| WO2021119545A1 (en) | 2019-12-11 | 2021-06-17 | Gritstone Bio, Inc. | Durable vaccination |
| KR102764120B1 (ko) | 2019-12-31 | 2025-02-06 | 엘릭서젠 쎄라퓨틱스, 인크. | 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달 |
| MX2022007910A (es) | 2019-12-31 | 2022-08-25 | Elixirgen Therapeutics Inc | Distribucion transitoria basada en temperatura de ácidos nucleicos y proteínas de zscan4 a células y tejidos. |
| US20230310581A1 (en) | 2020-04-27 | 2023-10-05 | Ohio State Innovation Foundation | A live attenuated measles virus vectored vaccine for sars-cov-2 |
| EP4168042A1 (en) | 2020-06-19 | 2023-04-26 | Ziphius Vaccines | Self-amplifying sars-cov-2 rna vaccine |
-
2020
- 2020-12-30 KR KR1020227026458A patent/KR102764120B1/ko active Active
- 2020-12-30 MX MX2022007905A patent/MX2022007905A/es unknown
- 2020-12-30 CN CN202080097486.9A patent/CN116134131A/zh active Pending
- 2020-12-30 WO PCT/US2020/067506 patent/WO2021138447A1/en not_active Ceased
- 2020-12-30 CN CN202310111339.8A patent/CN116196405A/zh active Pending
- 2020-12-30 JP JP2022540579A patent/JP7787075B2/ja active Active
- 2020-12-30 CA CA3162690A patent/CA3162690A1/en active Pending
- 2020-12-30 IL IL294290A patent/IL294290A/en unknown
- 2020-12-30 AU AU2020417800A patent/AU2020417800A1/en active Pending
- 2020-12-30 EP EP20908997.8A patent/EP4085130A4/en active Pending
-
2021
- 2021-08-17 US US17/404,901 patent/US11421248B2/en active Active
-
2022
- 2022-08-08 US US17/818,314 patent/US12060568B2/en active Active
-
2024
- 2024-07-10 US US18/769,203 patent/US20250027111A1/en active Pending
-
2025
- 2025-12-04 JP JP2025230795A patent/JP2026031695A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220372518A1 (en) | 2022-11-24 |
| US12060568B2 (en) | 2024-08-13 |
| CN116196405A (zh) | 2023-06-02 |
| KR20220129567A (ko) | 2022-09-23 |
| AU2020417800A1 (en) | 2022-07-14 |
| US20210381005A1 (en) | 2021-12-09 |
| JP2026031695A (ja) | 2026-02-24 |
| JP7787075B2 (ja) | 2025-12-16 |
| US20250027111A1 (en) | 2025-01-23 |
| CA3162690A1 (en) | 2021-07-08 |
| US11421248B2 (en) | 2022-08-23 |
| KR102764120B1 (ko) | 2025-02-06 |
| EP4085130A4 (en) | 2024-04-10 |
| IL294290A (en) | 2022-08-01 |
| JP2023508726A (ja) | 2023-03-03 |
| WO2021138447A1 (en) | 2021-07-08 |
| CN116134131A (zh) | 2023-05-16 |
| EP4085130A1 (en) | 2022-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schwenke et al. | Control of human endometrial stromal cell motility by PDGF-BB, HB-EGF and trophoblast-secreted factors | |
| Moodley et al. | Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury | |
| ES2676600T3 (es) | Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico | |
| ES2721180T3 (es) | Productos terapéuticos usando células adiposas y secreciones celulares | |
| BR112014031874A2 (pt) | método para preparar células-tronco em concentração elevada | |
| AR110962A1 (es) | Composiciones y métodos de tratamiento de hemoglobinopatías | |
| CL2024001429A1 (es) | Composiciones y métodos para inhibir la expresión de la proteína angiotensinógeno (agt) | |
| BR112021021921A2 (pt) | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica | |
| BR112019002584A2 (pt) | método para a geração de células do tipo células formadoras de colônia do mesoderma e/ou endoteliais apresentando capacidade de formação de vasos sanguíneos in vivo | |
| BR112015014752A2 (pt) | compostos e métodos para modulação de cinase, e indicações para isto | |
| CO6341654A2 (es) | Métodos y sistemas para predecir la respuesta de las células a un agente terapeútico | |
| MX2018015032A (es) | Composicion y metodo para reparacion y regeneracion muscular. | |
| UY30587A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus | |
| GB2571668A (en) | Stem cell conditioned media for clinical and cosmetic applications | |
| BR112015021869A2 (pt) | Domínios gla como agentes alvo | |
| MX2015012176A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| BR112016018489A2 (pt) | Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais | |
| BR112021012601A2 (pt) | Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso | |
| AR031281A1 (es) | Metodos para el tratamiento de trastornos proliferativos celulares | |
| BR112016000658A2 (pt) | pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática | |
| GB201202561D0 (en) | Treatment of skin disorders | |
| CO2020013050A2 (es) | Enzimas quinureninasa humanas y sus usos | |
| EP3617306A4 (en) | PROCESS FOR THE PRODUCTION OF MESENCHYMATIC STEM CELLS, MARKER OF THERAPEUTIC EFFECTS OF MESENCHYMATIC STEM CELLS, METHOD OF DETERMINATION OF THE THERAPEUTIC EFFECTS OF MESENCHYMATIC STEM CELLS, AND PREPARATION OF MESENCHYMATIC STEM CELLS, AND PREPARATION OF MESENCHYMA CELLS | |
| ES2647458A1 (es) | Sistema y método para regeneración capilar a base de microinjertos autólogos de células madre y su uso. | |
| Cao | Microenvironmental regulation of endometrial stem cells |